Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.48 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19520657 | 1.00 | F2 (0.54) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL2770110 | 1.00 | F2 (0.54) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL9314374 | 1.00 | F2 (0.54) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL1239590 | 1.00 | F2 (0.54) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL20502714 | 1.00 | F2 (0.54) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL6497247 | 0.96 | F2 (0.57) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL2119635 | 0.96 | F2 (0.57) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL2778546 | 0.96 | F2 (0.57) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL6850160 | 0.96 | F2 (0.57) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL2778544 | 0.96 | F2 (0.57) | F2OPRM1OPRD1OPRK1NPFFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 411 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154113-A1 | Microcrystalline Diketopiperazine Compositions and Methods | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2025-05-15 | — | — | US | claimed |
| EP-3587404-B1 | MICROCRYSTALLINE DIKETOPIPERAZINE COMPOSITIONS, METHODS FOR PREPARATION AND USE THEREOF | MANNKIND CORP (US) | 2022-07-13 | — | — | EP | claimed |
| US-20220074949-A1 | METHODS OF PREPARING SAMPLES FOR PROTEOMIC ANALYSIS | STRECK, INC. | 2022-03-10 | — | — | US | claimed |
| US-20220048868-A1 | Microcrystalline Diketopiperazine Compositions and Methods | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2022-02-17 | — | — | US | claimed |
| US-11192862-B2 | Microcrystalline diketopiperazine compositions and methods | MANNKIND CORPORATION (US) | 2021-12-07 | — | — | US | claimed |
| EP-3903106-A1 | METHODS OF PREPARING SAMPLES FOR PROTEOMIC ANALYSIS | Streck, Inc. (US) | 2021-11-03 | — | — | EP | claimed |
| US-11013692-B2 | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents | MANNKIND CORPORATION (US) | 2021-05-25 | — | — | US | claimed |
| US-20200339520-A1 | Microcrystalline Diketopiperazine Compositions and Methods | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2020-10-29 | — | — | US | claimed |
| US-10745359-B2 | Microcrystalline diketopiperazine compositions and methods | MANNKIND CORPORATION (US) | 2020-08-18 | — | — | US | claimed |
| WO-2020140035-A1 | METHODS OF PREPARING SAMPLES FOR PROTEOMIC ANALYSIS | STRECK, INC. (US) | 2020-07-02 | — | — | WO | claimed |
| EP-2114137-A2 | STABILISATION OF BIOLOGICAL CELL MARKERS | The University of Nottingham (GB) | 2009-11-11 | — | — | EP | claimed |
| WO-2008107724-A2 | STABILISATION OF BIOLOGICAL CELL MARKERS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2008-09-12 | — | — | WO | claimed |
| US-7235377-B2 | Determining hemostatic competence of blood by contacting blood sample with an effective amount of tissue factor to coagulate blood, and determinig amount of thrombin in blood sample at a prdetermined time point, where amount of thrombin is indicative of the hemostatic competence | THE UNIVERSITY OF VERMONT AND STATE AGRICULTURE COLLEGE (US) | 2007-06-26 | — | — | US | claimed |
| EP-1600777-A2 | A single-tube method and system for platelet function analysis | Helena Laboratories Corporation (US) | 2005-11-30 | — | — | EP | claimed |
| US-20050118653-A1 | Determining hemostatic competence of blood by contacting blood sample with an effective amount of tissue factor to coagulate blood, and determinig amount of thrombin in blood sample at a prdetermined time point, where amount of thrombin is indicative of the hemostatic competence | THE UNIVERSITY OF VERMONT AND STATE AGRICULTURE COLLEGE | 2005-06-02 | — | — | US | claimed |
| WO-2005017486-A2 | A GLOBAL TEST OF THE HEMOSTATIC SYSTEM | MANN KENNETH G (US) | 2005-02-24 | — | — | WO | claimed |
| US-20040219682-A1 | Single-tube method and system for platelet function analysis | HELENA LABORATORIES CORPORATION | 2004-11-04 | — | — | US | claimed |
| US-20040219681-A1 | Two-tube method and system for platelet function analysis using platelet count | HELENA LABORATORIES CORPORATION | 2004-11-04 | — | — | US | claimed |
| US-5370660-A | Apparatus and method for delivering a vessel plug into the body of a patient | CORDIS CORPORATION (US) | 1994-12-06 | — | — | US | claimed |
| US-5318524-A | Fibrin sealant delivery kit | CRYOLIFE, INC. (US) | 1994-06-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192862-B2 | Microcrystalline diketopiperazine compositions and methods | RRP15, DKK1, SPOP | F2 4460/4885OPRM1 3137/4885OPRD1 2888/4885 |
| US-20200339520-A1 | Microcrystalline Diketopiperazine Compositions and Methods | RRP15, DKK1, SPOP | F2 4460/4885OPRM1 3137/4885OPRD1 2888/4885 |
| US-20220048868-A1 | Microcrystalline Diketopiperazine Compositions and Methods | RRP15, DKK1, SPOP | F2 4460/4885OPRM1 3137/4885OPRD1 2888/4885 |
| US-20250154113-A1 | Microcrystalline Diketopiperazine Compositions and Methods | RRP15, DKK1, SPOP | F2 4460/4885OPRM1 3137/4885OPRD1 2888/4885 |
| US-10745359-B2 | Microcrystalline diketopiperazine compositions and methods | RRP15, DKK1, SPOP | F2 4460/4885OPRM1 3137/4885OPRD1 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.